We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Are Magnetic Nanoparticles Suitable for Cancer Therapy?

By Biotechdaily staff writers
Posted on 16 Jun 2008
A newly developed measuring procedure could help to investigate in some detail the behavior of magnetic nanoparticles and their potential for cancer therapy.

Researchers at the Physikalisch-Technische Bundesanstalt (PTB, Braunschweig, Germany) are researching the way magnetic nanoparticles—ranging from a few to several hundred nanometers in size--can be used as a new, promising means of fighting cancer. More...
The particles, released into the blood stream, serve as a carrier for specific drugs; they then course freely through the blood stream, until they fall under the influence of a targeting magnetic field, which holds them on to the tumor where the loaded drug releases its active agent. Besides the pharmaceutical effect, as an added bonus the electromagnetic field generates heat in the accumulated particles, destroying the tumor. Both therapeutic concepts have the advantage of largely avoiding undesired side effects on healthy tissue. In an attempt to find and investigate appropriate nanoparticles, the researchers at PTB developed magnetorelaxometry, a measurement technique in which the nanoparticles are magnetized for a brief period by a strong magnetic field in order to measure their relaxation after the switch-off of the field by means of superconducting quantum interferometers (SQUIDs).

Following magnetorelaxometry, conclusions on the nanoparticle aggregation behavior can then be drawn. Results in other fields have already served to optimize the paint drying process in the automobile industry, the thermal design of furnaces, as well as the monitoring of glass forming processes. In examining the cancer fighting potential of nanoparticles, conclusions can be drawn from measurements of their suspensions in serum or in whole blood. For example, it could be shown that certain nanoparticles in the blood serum form clusters with a diameter of up to 200 nanometers; since this a clear indication of aggregation, such nanoparticles would not appear to be suitable candidates for such therapy.

However, the high technical effort connected with the use of helium-cooled magnetic field sensors is still standing in the way of using this method routinely in practice. In a joint project with Braunschweig Technical University (Germany), the researchers at PTB are attempting to transfer the technique to a simpler technology, based on fluxgate magnetometers.


Related Links:
Physikalisch-Technische Bundesanstalt
Braunschweig Technical University

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Melanoma Panel
UltraSEEK Melanoma Panel
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.